Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average recommendation of “Moderate Buy” by the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $37.56.

Several equities research analysts have issued reports on the stock. Chardan Capital lowered their price target on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. BMO Capital Markets lowered their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. The Goldman Sachs Group reiterated a “sell” rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wedbush reiterated a “neutral” rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Finally, Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $56.00 to $11.00 in a research note on Monday, January 27th.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its holdings in Intellia Therapeutics by 4.1% in the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after purchasing an additional 3,596 shares during the period. Polar Asset Management Partners Inc. boosted its holdings in Intellia Therapeutics by 1,144.1% in the 4th quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company’s stock valued at $3,293,000 after purchasing an additional 259,700 shares during the period. GF Fund Management CO. LTD. bought a new stake in Intellia Therapeutics in the 4th quarter valued at about $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Intellia Therapeutics by 5.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company’s stock valued at $5,634,000 after purchasing an additional 23,173 shares during the period. Finally, Voloridge Investment Management LLC boosted its holdings in Intellia Therapeutics by 226.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 6.5 %

Shares of NASDAQ:NTLA opened at $8.70 on Friday. Intellia Therapeutics has a 12 month low of $8.30 and a 12 month high of $28.54. The company’s fifty day simple moving average is $10.11 and its 200 day simple moving average is $14.33. The firm has a market cap of $900.60 million, a price-to-earnings ratio of -1.60 and a beta of 1.97.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.